Investigation of the effects of some alkaloidal α1-adrenoceptor antagonists on human hyperplastic prostate

European Journal of Pharmacology

Volumn 374, Issue 3, 1999, Pages 503-510

  Guh, Jih Hwa ^a   Hsieh, Cheng Hsing ^a   Teng, Che Ming ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

1 Adrenoceptor antagonist; 1 Adrenoceptor subtype; Electrical field stimulation; Human; Hyperplastic prostate

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DISCRETAMINE; GOVADINE; N ALLYLSECOBOLDINE; NIFEDIPINE; PHENYLEPHRINE; PRAZOSIN; UNCLASSIFIED DRUG; XYLOPININE;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN TISSUE; MUSCLE CONTRACTION; MUSCLE TONE; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT; RECEPTOR AFFINITY; SPLEEN; VAS DEFERENS;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ALKALOIDS; ANIMALS; APORPHINES; BERBERINE; BERBERINE ALKALOIDS; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; HUMANS; MALE; MIDDLE AGED; MUSCLE CONTRACTION; NIFEDIPINE; PHENYLEPHRINE; POTASSIUM; PROSTATE; PROSTATIC HYPERPLASIA; RATS; RATS, WISTAR; SPLEEN; STEREOISOMERISM; VAS DEFERENS; VASODILATOR AGENTS;

EID: 0032967968     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00352-0     Document Type: Article

References (23)

1. 1-adrenoceptors and uroselectivity. Prostate. 30:1997;202-215.
2. Arunlakshana O., Schild H.O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. Chemother. 14:1959;48-52.
3. 1A-adrenergic antagonist. Urology. 51:1998;861-872.
4. Caine M. Clinical experiments with α-adrenoceptor antagonists in human prostatic hypertrophy. Fed. Proc. 45:1986;2604-2608.
5. 1-adrenoceptors. Eur. J. Pharmacol. 151:1988;333-335.
6. 1-adrenoceptor subtypes in tension response of human prostate to electrical field stimulation. Br. J. Pharmacol. 115:1995;142-146.
7. 2+ in smooth muscle. Nature. 329:1987;333-335.
8. 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br. J. Pharmacol. 97:1989;691-700.
9. 1-adrenoceptors in human prostate. Eur. J. Pharmacol. 107:1985;111-117.
10. Kitada S., Kumazawa J. Pharmacological characteristics of smooth muscle in benign prostatic hyperplasia and normal prostatic tissue. J. Urol. 138:1987;158-160.
11. 1D-adrenoceptor antagonist, isolated from Fissistigma glaucescens. Br. J. Pharmacol. 112:1994;1174-1180.
12. 1-adrenoceptor antagonists in vascular smooth muscle cells. J. Pharm. Pharmacol. 48:1996;629-634.
13. 1-adrenoceptors. Eur. Urol. 33:1998;2-6.
14. 1A-adrenoceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br. J. Urol. 80:1997;606-611.
15. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology. 51:1998;901-906.
16. Lu S.T., Wu Y.C., Led S.P. Alkaloids of Formosan Fissistigma and Goniothalamus species. Phytochemistry. 24:1985;1829-1834.
17. 2 and affinity constants for pharmacological competitive antagonists be estimated? J. Pharm. Pharmacol. 30:1978;312-313.
18. 1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053. Br. J. Pharmacol. 119:1996;407-415.
19. 1-Adrenergic receptor subtypes, inositol phosphates, and sources of cell calcium. Pharmacol. Rev. 40:1988;87-119.
20. 1-adrenoceptor subtypes in human prostate: comparison with those in rat vas deferens and spleen. Eur. J. Pharmacol. 265:1994;61-66.
21. Vaalasti A., Hervonen A. Autonomic innervation of the human prostate. Invest. Urol. 17:1980;293-297.
22. Vargas H.M., Gorman A.J. Vascular α-1 adrenergic receptor subtypes in the regulation of arterial pressure. Life Science. 57:1995;2291-2308.
23. Wilde M.I., McTavish D. Tamsulosin: a review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs. 52:1996;883-898.